BR112017015455A2 - agentes de imagiologia pet - Google Patents
agentes de imagiologia petInfo
- Publication number
- BR112017015455A2 BR112017015455A2 BR112017015455-2A BR112017015455A BR112017015455A2 BR 112017015455 A2 BR112017015455 A2 BR 112017015455A2 BR 112017015455 A BR112017015455 A BR 112017015455A BR 112017015455 A2 BR112017015455 A2 BR 112017015455A2
- Authority
- BR
- Brazil
- Prior art keywords
- imaging agents
- pet imaging
- formula
- preparation
- relates
- Prior art date
Links
- 239000012216 imaging agent Substances 0.000 title abstract 3
- ANASFDJHMYPKHS-UHFFFAOYSA-N 2-benzyl-5-methyltetrazole Chemical class N1=C(C)N=NN1CC1=CC=CC=C1 ANASFDJHMYPKHS-UHFFFAOYSA-N 0.000 abstract 1
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 abstract 1
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nuclear Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105336P | 2015-01-20 | 2015-01-20 | |
| US62/105,336 | 2015-01-20 | ||
| PCT/IB2016/050276 WO2016116875A1 (en) | 2015-01-20 | 2016-01-20 | Pet imaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017015455A2 true BR112017015455A2 (pt) | 2018-01-23 |
Family
ID=55300733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017015455-2A BR112017015455A2 (pt) | 2015-01-20 | 2016-01-20 | agentes de imagiologia pet |
Country Status (12)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170103960A (ko) | 2015-01-20 | 2017-09-13 | 노파르티스 아게 | Pet 영상화제 |
| TWI809597B (zh) * | 2020-12-16 | 2023-07-21 | 美商美國禮來大藥廠 | 預靶向造影劑 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0224917D0 (en) * | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
| WO2005043300A2 (en) | 2003-10-20 | 2005-05-12 | Empirix, Inc. | Computer language interpretation and optimization for server testing |
| EP1740565A2 (en) | 2004-04-28 | 2007-01-10 | ICOS Corporation | Arylphenylamino-, arylphenylamide-, and arylphenylether-sufide derivatives |
| WO2005121094A1 (en) | 2004-06-09 | 2005-12-22 | Pfizer Limited | Piperazine and piperidine derivatives as anti-hiv-agents |
| CN101429161A (zh) * | 2008-12-05 | 2009-05-13 | 常熟理工学院 | Pet显像剂前体异喹啉甲酰胺衍生物的合成方法 |
| JP5767205B2 (ja) * | 2009-04-02 | 2015-08-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | オートタキシン阻害剤としての複素環式化合物 |
| WO2012020567A1 (en) | 2010-08-09 | 2012-02-16 | Raqualia Pharma Inc. | Acyl piperazine derivatives as ttx-s blockers |
| EP2606031B1 (en) * | 2010-08-20 | 2017-09-27 | Amira Pharmaceuticals, Inc. | Autotaxin inhibitors and uses thereof |
| SI2861566T1 (sl) * | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| EP2935249B1 (en) | 2012-12-19 | 2018-12-12 | Novartis AG | Autotaxin inhibitors |
| PT3022202T (pt) * | 2013-07-18 | 2019-09-03 | Novartis Ag | Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo |
| KR20170103960A (ko) | 2015-01-20 | 2017-09-13 | 노파르티스 아게 | Pet 영상화제 |
-
2016
- 2016-01-20 KR KR1020177022757A patent/KR20170103960A/ko not_active Withdrawn
- 2016-01-20 MX MX2017009452A patent/MX2017009452A/es unknown
- 2016-01-20 AU AU2016209906A patent/AU2016209906A1/en not_active Abandoned
- 2016-01-20 CN CN201680016753.9A patent/CN107406419B/zh active Active
- 2016-01-20 EA EA201791643A patent/EA201791643A1/ru unknown
- 2016-01-20 ES ES16702985T patent/ES2828715T3/es active Active
- 2016-01-20 US US15/544,850 patent/US10450298B2/en active Active
- 2016-01-20 WO PCT/IB2016/050276 patent/WO2016116875A1/en not_active Ceased
- 2016-01-20 EP EP16702985.9A patent/EP3247706B1/en active Active
- 2016-01-20 CA CA2974311A patent/CA2974311A1/en not_active Withdrawn
- 2016-01-20 BR BR112017015455-2A patent/BR112017015455A2/pt not_active Application Discontinuation
- 2016-01-20 JP JP2017555866A patent/JP6723264B2/ja not_active Expired - Fee Related
-
2019
- 2019-09-24 US US16/581,086 patent/US10865195B2/en active Active
-
2020
- 2020-06-22 JP JP2020106739A patent/JP2020158532A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10450298B2 (en) | 2019-10-22 |
| CN107406419B (zh) | 2020-09-11 |
| JP2018511648A (ja) | 2018-04-26 |
| EP3247706B1 (en) | 2020-07-08 |
| US20200017474A1 (en) | 2020-01-16 |
| WO2016116875A1 (en) | 2016-07-28 |
| CN107406419A (zh) | 2017-11-28 |
| JP2020158532A (ja) | 2020-10-01 |
| CA2974311A1 (en) | 2016-07-28 |
| MX2017009452A (es) | 2017-11-08 |
| AU2016209906A1 (en) | 2017-08-03 |
| KR20170103960A (ko) | 2017-09-13 |
| JP6723264B2 (ja) | 2020-07-15 |
| US20180273509A1 (en) | 2018-09-27 |
| US10865195B2 (en) | 2020-12-15 |
| EP3247706A1 (en) | 2017-11-29 |
| ES2828715T3 (es) | 2021-05-27 |
| EA201791643A1 (ru) | 2017-11-30 |
| CN107406419A8 (zh) | 2018-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120529T1 (el) | Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων | |
| BR112017023161A2 (pt) | composições de ácido obeticólico e métodos de uso | |
| MX380810B (es) | Sondas para la proyección de imagen de la proteína huntingtina. | |
| BR112016025048A2 (pt) | compostos e composições como agonistas do receptor tipo toll7 | |
| BR112016014731A2 (pt) | Anticorpos anti-baff | |
| MX2016010213A (es) | Formulaciones farmaceuticas novedosas. | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| BR112019005329A2 (pt) | composições de oligossacarídeos de leite humano purificadas | |
| CR20160374A (es) | Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina | |
| UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| BR112018003331A2 (pt) | sondas para imagear proteína huntingtina | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| CO2019013718A2 (es) | Anticuerpos anti-trkb | |
| EA201790432A1 (ru) | Зонды для визуализации белка хантингтина | |
| MX386798B (es) | Sondas para la proyección de imagen de la proteína huntingtina. | |
| BR112017004134A2 (pt) | ?sondas para imageamento de proteína de huntingtina? | |
| UY35747A (es) | Derivados sustituidos de fenilalanina | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| BR112017002173A2 (pt) | anticorpos semelhantes à angiopoietina e métodos de uso | |
| UY35746A (es) | Derivados de fenilalanina sustituidos | |
| BR112019000946A8 (pt) | Compostos para imagiologia dos agregados da proteína tau |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |